Purine

Purine

SCHEMBL731405

Cc1ncnc2nc[nH]c12.c1ncc2[nH]cnc2n1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.44
LRRK2 Q5S007 2/20 0.44
TP53 P04637 2/20 0.44
HSD17B10 Q99714 2/20 0.44
CHEK1 O14757 1/20 0.44
AURKA O14965 1/20 0.44
CHEK2 O96017 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
PRKACA P17612 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
MARK3 P27448 1/20 0.44
RPS6KA3 P51812 1/20 0.44
PRKCD Q05655 1/20 0.44
MARK2 Q7KZI7 1/20 0.44
PI4KA P42356 2/20 0.43
PI4K2B Q8TCG2 2/20 0.43
PI4K2A Q9BTU6 2/20 0.43
PI4KB Q9UBF8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL375936 0.84 LRRK2 (0.57) PDPK1LRRK2TP53HSD17B10CHEK1
Purine SCHEMBL27278493 0.82 ALDH1A1 (0.44) PDPK1LRRK2TP53HSD17B10CHEK1
Purine SCHEMBL29365913 0.82
Purine SCHEMBL6421380 0.82 ALDH1A1 (0.47) PDPK1LRRK2TP53HSD17B10CHEK1
Purine SCHEMBL2120554 0.82 ALDH1A1 (0.47) PDPK1LRRK2TP53HSD17B10CHEK1
Purine SCHEMBL29703771 0.82 ALDH1A1 (0.47) PDPK1LRRK2TP53HSD17B10CHEK1
Purine SCHEMBL3158 0.82
Purine SCHEMBL30862524 0.82
Purine SCHEMBL27575443 0.81 ALDH1A1 (0.42) PDPK1LRRK2TP53HSD17B10CHEK1
Mercaptopurine Anhydrous SCHEMBL1820743 0.81 PI4KA (0.43) PDPK1LRRK2TP53HSD17B10CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3478325-B1 ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS RES FOUND DEV (US) 2024-07-17 EP disclosed
CN-118355023-A Method for producing therapeutic immune cells with enhanced metabolic adaptation and compositions thereof 得克萨斯大学体系董事会 2024-07-16 CN disclosed
EP-4392061-A1 CD3 EPSILON CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF The Regents of the University of Colorado, a body corporate (US) 2024-07-03 EP disclosed
CN-118265535-A Engineered NK cells with optimally signaling CAR constructs 得克萨斯大学体系董事会 2024-06-28 CN disclosed
WO-2024137789-A2 CD3 AND ITCR EXPRESSING ENGINEERED NATURAL KILLER CELLS WITH ENHANCED FUNCTION FOR ADOPTIVE IMMUNOTHERAPY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-06-27 WO disclosed
CN-118251227-A Antibody-loaded immune cells and methods for cancer treatment 得克萨斯大学体系董事会 2024-06-25 CN disclosed
CN-118234744-A Chimeric antigen receptor targeting HLA-G positive cancers 得克萨斯大学体系董事会 2024-06-21 CN disclosed
US-20240189357-A1 CHIMERIC ANTIGEN RECEPTORS TO TARGET CD5-POSITIVE CANCERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-06-13 US disclosed
EP-4380967-A1 LAT ACTIVATING CHIMERIC ANTIGEN RECEPTOR T CELLS AND METHODS OF USE THEREOF The Regents of the University of Colorado, a body corporate (US) 2024-06-12 EP disclosed
CN-118119643-A BCMA targeting compositions and methods of use thereof 武田药品工业株式会社 2024-05-31 CN disclosed
WO-2003012049-A2 METHODS AND COMPOSITION CONCERNING HERPES VIRUS US3 AND BAD-INVOLVED APOPTOSIS UNIVERSITY OF CHICAGO (US) 2003-02-13 WO disclosed
WO-2003007889-A2 THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS RESEARCH DEVELOPMENT FOUNDATION (US) 2003-01-30 WO disclosed
US-20020143062-A1 Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-10-03 US disclosed
WO-2001025255-A9 NOVEL ZINC FINGER PROTEIN BAYLOR COLLEGE MEDICINE (US) 2002-09-26 WO disclosed
WO-2002069886-A2 MODIFIED PROTEINS, DESIGNER TOXINS, AND METHODS OF MAKING THEREOF RESEARCH DEVELOPMENT FOUNDATION (US) 2002-09-12 WO disclosed
WO-2002041871-A2 COMPOSITION COMPRISING AN IMEXON OR DERIVATIVES THEREOF AND LIPIDS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-05-30 WO disclosed
WO-2002032413-A2 A METHOD TO INCORPORATE N-(4-HYDROXYPHENYL) RETINAMIDE IN LIPOSOMES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-04-25 WO disclosed
EP-1180016-A2 METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES Introgen Therapeutics, Inc. (US) 2002-02-20 EP disclosed
WO-2001025255-A2 NOVEL ZINC FINGER PROTEIN BAYLOR COLLEGE OF MEDICINE (US) 2001-04-12 WO disclosed
WO-2000071096-A2 METHODS AND COMPOSITIONS FOR NON-VIRAL GENE THERAPY FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES INTROGEN THERAPEUTICS, INC. (US) 2000-11-30 WO disclosed